Specialized Research

Dermorphin

Also known as: Dermorfina, Dermorpin

Molecular Identifiers

Molecular Formula

C40H50N8O10

CAS Number

77614-16-5

PubChem CID

5485199

Molecular Weight

802.88 Da

Overview

Natural opioid heptapeptide isolated from the skin of Phyllomedusa frogs, with a molecular weight of approximately 803.88 Da. Contains the non-standard amino acid D-alanine at position 2, conferring exceptional potency and selectivity for the mu-opioid receptor. Considered one of the most potent known peptide analgesics, with 30-40 times greater activity than morphine.

The scientific interest in Dermorphin lies in its analgesia: it is an extremely potent and selective mu-opioid receptor agonist, inhibiting nociceptive transmission and substance P release, with activity described as 30-40 times greater than morphine in preclinical studies. For the same reason, it carries a high risk of respiratory depression, sedation, tolerance, and dependence.

It is not approved as a medicine by any agency (FDA, EMA, ANVISA), and its use is restricted to laboratory research. There is no legitimate clinical prescription or compounding context for human use. There is documented illicit use as a doping agent in horse racing, and its handling is controlled in several countries due to abuse potential.

It was originally isolated from the skin of Phyllomedusa frogs in the Amazon, being one of the first natural opioid peptides described to contain a D-amino acid — in this case, D-alanine at position 2 — a feature that gives it unusual resistance to enzymatic degradation and high potency.

Extended notation: Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂

Contains D-alanine at position 2

Half-life

~2-4 hours

Administration Route

Subcutaneous

Category

Specialized Research

Mechanism of Action

  • Potent and selective mu-opioid receptor (MOR) agonism
  • Deep analgesia via inhibition of nociceptive transmission
  • Modulation of the descending pain control pathway
  • Inhibition of substance P release in sensory neurons
  • Central and peripheral action on opioid receptors

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 1-5 mcg/kg (research only)
Frequency Single dose or per research protocol
Timing Acute administration under supervision
Duration Acute use only (not indicated for prolonged use)

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Respiratory depression
  • Sedation
  • Nausea
  • Rapid tolerance
  • Dependence (potential)

Product Properties

Purity >98%
Appearance White lyophilized powder
Solubility Soluble in water and bacteriostatic water
Source Solid-phase peptide synthesis (SPPS)
Storage Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles.

Presentations & Preparation

Vials of Dermorphin found in the research market:

5 mg10 mg

Reconstitution

  • Diluent: Sterile saline solution
  • Volume: 1 ml per vial
  • Reconstitute with sterile saline solution
  • Gently swirl until fully dissolved — never shake
  • Prepare only in a controlled research environment

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Use immediately after reconstitution
  • Protect from direct light
  • Discard unused solution
  • Long-term storage at -20°C
Reconstitution Calculator

Scientific Studies

Published studies on Dermorphin.

Related Peptides